Mobile

An Expanded Access Open Label Study of CB7630 (Abiraterone Acetate) in Patients with Advanced Prostate Cancer Who Have Completed CB7630 Clinical Study COU-AA-001

Update Il y a 5 ans
Reference: EUCTR2006-006755-12

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To provide access to CB7630 for patients who have completed 12 cycles of abiraterone acetate treatment and continue to receive clinical benefit from such a treatment.

Inclusion criteria

  • Hormone refractory prostate cancer

Links